Dr. Schiller on the Importance of Genomic Testing in AML

Video

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia.

Gary J. Schiller, MD, director, Bone Marrow/Stem Cell Transplantation and professor of hematology/oncology, David Geffen School of Medicine, UCLA, underscores the importance of genomic testing in acute myeloid leukemia (AML).

It's important to remember that AML is not just one disease, says Schiller. He adds that he remembers urging his colleagues to perform cytogenetics and fluorescence in situ hybridization testing in the past. These tests have become standardized but newer approaches have also emerged, such as molecular testing, next-generation sequencing, and testing with probes.

These approaches have yet to become a standard part of routine practice, but the implications of performing these tests are significant, adds Schiller. For example, the results can help guide initial therapy, therapy after relapse, and inform the use of transplant. Schiller’s advice is to develop molecular testing panels at academic institutions and commercial laboratories to more adequately assess patients with AML.

Related Videos
Amy DeZern, MD, MHS, an expert on MDS
Andrew Brunner, MD, an expert on MDS
Jaime R. Merchán, MD, Sylvester Comprehensive Cancer Center
Rona Yaeger, MD
Mitchell S. Cairo, MD, and Sergio Giralt, MD, experts on veno-occlusive disease
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital